Please login to the form below
avibactam
This page shows the latest avibactam news and features for those working in and with pharma, biotech and healthcare.
Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
Latest news
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
-
AZ slims down again with sale of antibiotics to Pfizer
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
-
AZ gets EU green light for new antibiotic Zavicefta
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... AZ and Actavis are also testing avibactam in combination with other beta
-
Merck starts pivotal trials of new antibiotic combination
aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.
-
CHMP backs AZ's 'superbug' antibiotic product
In the US, Actavis (now operating as Allergan) has been granted FDA approval for another combination of ceftazidime and avibactam, which is sold as Avycaz. ... Actavis gained rights to the combination after buying Forest Labs, which originally developed
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- FDA approves Roche’s Actemra COVID-19 trial
- 3 ways to increase patient retention rates in clinical trials
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
Quick links
Infographics
